Discovery of immunopotentiatory drugs: Current and future strategies

Clinical and Experimental Immunology

Volumn 130, Issue 3, 2002, Pages 363-369

  Rhodes, John ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Antigen presenting cell; Drug discovery; Imiquimod; Immunomodulation; T cell; Toll like receptors; Tucaresol

Indexed keywords

IMIQUIMOD; IMMUNOSTIMULATING AGENT; INSULIN; INTERFERON; LITHIUM SALT; METHISOPRINOL; MONOCLONAL ANTIBODY; RESIQUIMOD; RIBAVIRIN; THALIDOMIDE;

CHEMISTRY; CLINICAL TRIAL; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG INDUSTRY; DRUG QUALITY; DRUG SCREENING; DRUG STABILITY; DRUG SYNTHESIS; EPSTEIN BARR VIRUS; ERYTHEMA NODOSUM LEPROSUM; GENETICS; GENITAL HERPES; GENOMICS; HEPATITIS C; HERPES SIMPLEX; HOST RESISTANCE; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOPOTENTIATION; MACROMOLECULE; MOLLUSCUM CONTAGIOSUM; NONHUMAN; PANENCEPHALITIS; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; QUALITY CONTROL; REVIEW; SKIN DEFECT; VACCINATION; VIRUS ENCEPHALITIS;

ADJUVANTS, IMMUNOLOGIC; AMINOQUINOLINES; ANIMALS; ANTIGEN-PRESENTING CELLS; BENZALDEHYDES; BENZOATES; DROSOPHILA PROTEINS; DRUG DESIGN; HUMANS; ISCOMS; MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; TH1 CELLS; TOLL-LIKE RECEPTORS;

EID: 0036444201     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2002.02016.x     Document Type: Review

References (54)

1. Masihi KN. Immunomodulatory agents for the prophylaxis and therapy of infections. Int J Antimicrob Agents 2000; 14:181-91.
2. Sykes RB. New Medicines, the Practice of Medicine and Public Policy. Rock Carling Fellowhip of the Nuffield Trust. London: The Stationary Office, 2000.
3. Buckley RH. Primary immunodeficiency diseases. In: Paul W, ed. Fundamental Immunology, 4th Edn. New York: Lippincot-Raven, 1999:1427-53.
4. Miller RL, Gerster JF, Owens ML, Slade HB, Tomami MA. Imiquimod applied topically. A novel class of immune response modifier and new class of drug. Int J Immunopharm 1999; 21:1-14.
5. Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 2001; 48:751-5.
6. Testerman TL, Gerster JF, Imbertson LM, Reiter MJ, Miller RL, Gibson SJ, Wagner TL, Tomai MA. Cytokine induction by the immunomodulators imiquimod and S-27609. J Leukocyte Biol 1995; 58:365-72.
7. Weeks CE, Gibson SJ. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res 1994; 14:81-5.
8. Harrison CJ, Miller RL, Bernstein DI. Post-therapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod inguinea pigs. Antimicrob Agents Chemother 1994; 38:2059-64.
9. Bernstein DI, Harrison CJ, Tomai MA, Miller RL. Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis, 2001; 183:44-849.
10. Arevelo I, Ward B, Miller R, Meng T-C, Najar E, Alvarez E, Matlashewski G, Lianos-Cuentas A. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33:1874-51.
11. Hemmi H, Kaisho T, Takeuchi O et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent pathway. Nature Immunol 2002; 3:196-200.
12. Jurk M, Heil F, Vollmer J, Schetter C, Krieg M, Wagner H, Lipford G, Bauer S. Human TLR-7 or TLR-8 independently confer responsiveness to the antiviral compound R-848. Nature Immunol 2002; 3:499.
13. Medzhitov R, Janeway CA. Innate immune response recognition and control of adaptive immune responses. Sem Immunol 1998; 10:351-3.
14. Medzhitov R, Janeway CA. How does the immune system distinguish self from nonself? Sem Immunol 2000; 12:185-8.
15. Medzhitov R, Janeway CA. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296:298-300.
16. Hemmi H, Takeuchi O, Kawai T et al. A toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5.
17. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappa B by toll-like receptor 3. Nature 2001; 413:732-8.
18. Hayashi F, Smith KD, Ozinsky A et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature 2001; 410:1099-103.
19. Yang RB, Mark MR, Gray A et al. Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling. Nature 1998; 395:284-8.
20. Seiling PA, Modlin RL. Toll-like receptors. Mammalian 'taste receptors' for a smorgasbord of microbial invaders. Current Opinion Microbiol 2002; 5:70-5.
21. Rhodes J. Evidence for an intercellular covalent reaction essential in antigen specific T cell activation. J Immunol 1989; 143:1482-9.
22. Gao X-M, Rhodes J. An essential role for constitutive Schiff base-forming ligands in antigen presentation to murine T cell clones. J Immunol 1990; 144:2883-90.
23. Rhodes J. E-Rosettes provide an analogue for Schiff base formation in specific T cell activation. J Immunol 1990; 145:463-9.
24. Zheng B, Brett S, Tite JP, Lifely MR, Brodie TA, Rhodes J. Galactose oxidation in the design of immunogenic vaccines. Science 1992; 256:1560-3.
25. Rolan PE, Parker JE, Gray SJ, Weatherley BC, Ingram J, Leavens W, Wootton R, Posner J. The pharmacokinetics, tolerability and pharmacodynamics of tucaresol (589C80; 4[2-formyl-3-hydroxyphenoxymethyl] benzoic acid), a potential anti-sickling agent, following oral administration to healthy subjects. Brit J Clin Pharmacol 1993; 35:419-25.
26. Rhodes J, Chen H, Hall SR, Beesley JE, Jenkins DC, Collins P, Zheng B. Therapeutic potentiation of the immune system by costimulatory Schiff base-forming drugs. Nature 1995; 377:71-5.
27. Chen H, Hall S, Heffernan B, Thompson NT, Rogers MV, Rhodes J. Convergence of Schiff base costimulatory signaling and TCR signaling at the level of mitogen activated protein kinase ERK2. J Immunol 1997; 159:2274-81.
28. Hall SR, Rhodes J. Schiff base-mediated co-stimulation primes the T-cell-receptor-dependent calcium signalling pathway in CD4 T-cells. Immunology 2001; 104:50-7.
29. Noble A, Truman JP, Vyas B, Vukamanovic-Stejic M, Hirst WJ, Kemeny DM. The balance of protein kinase C and calcium signaling directs T cell subset development. J Immunol 2000; 164:1807-13.
30. Noble A, Thomas MJ, Kemeny DM. Early Th1/Th2 cell polarisation in the absence of IL-4 and Il-12: T cell receptor signaling regulates the response to cytokines in CD4 and CD8 T-cells. Euro J Immunol 2001; 31:2227-35.
31. Smith AC, Yardley V, Rhodes J, Croft SL. Activity of the novel immunomodulatory compound tucaresol against experimental visceral leishmaniasis. Antimicrob Agents Chemother 2000; 44:1494-8.
32. Kirkwood JM, Schucter LM, Donelly S et al. A novel immunopotentiatory agent, tucaresol: Results from a multicenter, pilot study in patients with metastatic melanoma. Proc Am Assoc Cancer Res 1997; 38:402.
33. Clerici M, Bosis S, Rizzardi G, Comombo F, Rhodes J, Bray D, Piconi S. In vitro immunomdulatory properties of tucaresol in HIV infection. Clin Immunol 2000; 97:211-20.
34. Gori A, Trabattoni D, Bandera A et al. Safety and immunomodulatory properties of tucaresol. In: Gatelli J, Casabona J, eds. HIV-Infected Patients. XIVth International AIDS Confererce. Barcelona:, 2002: Poster no: MoPeA3032.
35. Johnson D. Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors. International Patent (PCT) Application No. WO 01/70663 A2 2001.
36. Hazen SL, Hsu FF, Heinecke JW. p-hydrophenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phactocytes: A chloride dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase. J Biol Chem 1996; 271:1861-7.
37. 2-chloride system of phagocytes, covalently modifiese ε-amino groups of protein lysine residues. J Biol Chem 1997; 272:16990-8.
38. Campoli-Richards DM, Sorkin EM, Heel RC. Inosine pranobex. A preliminary review of its pharmacodynamics and pharmacokinetic properties, and therapeutic efficacy. Drugs 1986; 32:383-424.
39. Kovacs JA, Powell F, Voeller D, Allegra CJ. Inhibition of pneumocystis-carinii dihydropteroate synthetase by para-acetoamidobenzioc acid - Possible mechansims of action of isoprinosine in human immunodeficiency virus infection. Antimicrob Agents Chemother 1993; 37:1227-31.
40. Snell NJ. Ribavirin. Current status of a broad spectrum anti-viral agent. Expert Opin Pharmacother 2001; 2:1317-24.
41. Souvignet C, Zarski JP. Combination treatment for chronic hepatitis C. What is the role of ribavirin. Fundamental Clin Pharmacol 2000; 14:321-5.
42. Eriksson B, Helgstrand E, Johansson NG et al. Inhibition of influenza virus ribonucleic acid polymerase by ribavirin triphosphate. Antimicrob Agents Chemother 1977; 11:946-51.
43. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JYN, Hong Zhi Andino R, Cameron CE. The broad spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nature Med 2000; 6:1375-9.
44. Cameron CE, Castro C. The mechanism of action of ribavirin: Lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opinion Infect Dis 2001; 14:757-64.
45. Eriksson T, Bjorkman S, Höglund P. Clinical pharmacology of thalidomide. Euro J Clin Pharm 2001; 57:365-76.
46. Meierhofer C, Dunzendorfer S, Wiedermann CJ. Theoretical basis for the activity of thalidomide. Biodrugs 2001; 15:681-703.
47. Hussein MA, Juturi JV, Lieberman I. Multitple myeloma. Present and future. Curr Opin Oncol 2002; 14:31-5.
48. Leonard WJ, Type I. Cytokines and interferons and their receptors. In: Paul W, ed. Fundamental Immunology, 4th Edn. New York: Lippincot-Raven, 1999:741-74.
49. Krakauer T, Vilcek J, Oppenheim JJ. Proinflammatory cytokines. TNFα and IL-1 families, TGF-β, and others. In: Paul W, ed. Fundamental Immunology, 4th Edn. New York: Lippincot-Raven, 1999: 775-811.
50. Bluestone JA, Khattri R, van Seventer GA. Accessory molecules. In: Paul W, ed. Fundamental Immunology, 4th Edn. New York: Lippincot-Raven, 1999:449-78.
51. Majetis R, Weiss A. Regulatory mechanisms for receptor protein tyrosine phosphatases. Chem Rev 2001; 101:2441-8.
52. Cantrell DA. T-cell antigen receptor signal transduction. Immunology 2002; 105:369-74.
53. Dong C, Flavell RA. MAP kinases in the immune response. Ann Rev Immunol 2002; 20:55-72.
54. + T-cells. Nature Immunol 2002; 3:449-557.